Why the study?
Should thrombin time assay be incorporated for acute stroke patients suspected to be taking dabigatran to ensure safe thrombolysis?
Should thrombin time assay be incorporated for acute stroke patients suspected to be taking dabigatran to ensure safe thrombolysis?
Incorporating a thrombin time assay may improve the safety of stroke thrombolysis in patients suspected of taking dabigatran.
May support thrombin time testing before thrombolysis in dabigatran patients; leaves open prospective validation in stroke cohorts.
Stroke thrombolysis is becoming a common practice in Australian and New Zealand hospitals. There are no established guidelines for thrombolysis of patients who are taking dabigatran, and accurate medication reconciliation may not be possible. Patients with normal activated partial thromboplastin time are unlikely to have clinically significant dabigatran concentration in the blood. For safest outcomes, we suggest incorporating thrombin time assay for acute stroke patients suspected to be taking dabigatran.
No takes yet. Share an insight, caveat, or question.
Jayathissa et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: